Galenica: Historic growth despite a challenging market

Galenica AG announces a 5.5% increase in sales, exceeding CHF 4 billion for the first time. All business segments contributed to this growth, with a particular focus on pharmacies and wholesale. The newly integrated Diagnostics segment also made a significant contribution. Demand for prescription medications and dietary supplements was especially strong.

EBIT forecasts for 2025 are optimistic, with an expected increase of between 10 and 12%. Galenica has strengthened its pharmacy network, reaching 381 sites, and has successfully developed its digital customer experience.

In a challenging market environment, the Products & Brands segment grew by 6.2%, despite a decline in exports. Furthermore, the acquisition of Labor Team enabled Galenica to expand its reach in the diagnostics market. The Logistics & IT sector continued to grow, with a 4.8% increase in sales.